- Wave of Debt Payments Facing US Government
- US Job Losses to Bottom out Next Quarter: NABE
- Obama Jobs Forum May Be More Political Than Practical
- Late Payments on Credit Cards Drop in Third Quarter
- Smallest US Businesses Borrowing Again: PayNet
- Little Sign of Inflation on the Horizon: IMF
- Kraft Weighs Higher Cadbury Bid as Rivals Circle
- MBS Program Should be Extended: Fed's Bullard
- Tyson Food Profit Beats Estimates
- Losey: Asset Allocation At Retirement
- Farrell: Obama Hectored, Ignored and Restricted?
- Don't Dwell on Investment Mistakes; Move on, Like Buffett
- CNBC VIDEO: Warren Buffett & Bill Gates 'Walk & Talk' at Columbia University
- U.S. Stocks Slip, Dollar Rises
- How Stock Investors Can Play Holiday Travel
- Time Lapse World Series Is A Great Play
- Hirschhorn: Greed...or Fear
- My Top 10 Tech Toys for the Holidays
- Ohio, other states giving venison donations a lift
- Macquarie sells interest in local power business
- NM wants company to take responsibility for cavern
- Retirement readiness index says if you're on track
- Transocean's Saltiel tapped for COO position
- China tells banks to control lending
- Denied relief, W.Va. schools ready to sue
- New Hampshire considering paid sick leave mandate
- Travelzoo's Loughlin to become CEO in 2010
Text Size 
PARIS - French drug maker Sanofi-Aventis SA said Monday it has received regulatory approval in France for Panenza, its vaccine against the swine flu virus.
Panenza, made by the company's vaccine division Sanofi Pasteur, is a non-adjuvanted vaccine. Adjuvants are chemical compounds used to boost the immune system and stretch the vaccine's active ingredient.
Some countries, including the United States, refuse to use adjuvants in their vaccines because there is limited information on the safety of vaccines with adjuvants for two groups — pregnant women and children older than six months — thought to be particularly vulnerable in a pandemic.
Sanofi Pasteur is seeking approval for Panenza in six European Union countries: Belgium, France, Germany, Italy, Luxembourg and Spain.
Sanofi Pasteur's Humenza vaccine, which is made with adjuvants, is currently being reviewed by European health authorities with a decision expected in December, company spokesman Pascal Barollier said.
Print
Email
- Warren Buffett and Bill Gates discuss the economy and other subjects with CNBC's Becky Quick.
- The show attracts a big TV audience every year, but this year it may take on even more importance.
- …you'll want to be prepared. Tips for getting the most out of the post-Thanksgiving shopping frenzy.
- Congressman Ron Paul explains to Squawk Box why he’s pushing legislation to audit the Federal Reserve.
- A Macau casino will open Asia's first Michael Jackson shrine after its owners made a key purchase at a US auction.
- CNBC’s technology reporter Jim Goldman guides you through the best gadgets to buy this holiday season.
Data is a real-time snapshot *Data is delayed at least 15 minutes